Furthermore, weight loss is likely to remain a concern in non-diabetic patients, particularly if they are already frail or undernourished, and especially in the context of the semaglutide trial, given its enhanced efficacy in promoting weight reduction [39]
It has since been studied across a broad range of neuroendocrine and stress-related applications beyond its original sleep-induction discovery
Future research should aim to clarify the GLP-1RA-specific benefits and mechanisms in HFpEF, which would help to integrate them more effectively into therapeutic regimens.
Therapeutically, this inhibition results in decreased systemic estrogen levels and increased systemic testosterone levels, which is therapeutic in estrogen-dependent breast cancers and in disease states where increased testosterone is important
When GLP-1 levels increase, the body feels fuller for longer, reducing cravings and overall calorie intake